Search research articles
Contact Us
Filters
Showing results (241-250 of 260) with videos related to
Page
of 26
Sort By:
Hemasphere
|
October 9, 2024
Combined inhibition of CTPS1 and ATR is a metabolic vulnerability in p53-deficient myeloma cells
Romane Durand, Céline Bellanger, Géraldine Descamps, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 14, 2026
Efficacy of targeted therapies for metastatic small bowel adenocarcinoma treatment: A retrospective study by AGEO
Emeric Boisteau, Alice Boilève, David Tougeron, et al.
ESMO Real World Data and Digital Oncology
|
February 6, 2026
Characteristics and impact of real-world evidence studies in oncology: comprehensive mapping review of publications evaluating targeted therapies in solid tumours
A Pellat, T Grinda, P Cresta Morgado, et al.
Blood
|
August 10, 2023
CARD11 gain of function upregulates BCL2A1 expression and promotes resistance to targeted therapies combination in B-cell lymphoma
Salomé Decombis, Celine Bellanger, Yannick Le Bris, et al.
Addiction (Abingdon, England)
|
March 22, 2022
Effectiveness and cost-effectiveness of face-to-face and electronic brief interventions versus screening alone to reduce alcohol consumption among high-risk adolescents presenting to emergency departments: three-arm pragmatic randomized trial (SIPS Junior high risk trial)
Paolo Deluca, Simon Coulton, Mohammed Fasihul Alam, et al.
Blood Advances
|
December 12, 2018
p53 regulates CD46 expression and measles virus infection in myeloma cells
Anne Lok, Geraldine Descamps, Benoit Tessoulin, et al.
Gastrointestinal Endoscopy
|
February 19, 2026
Ability of computed tomography and endoscopic ultrasound to predict pTNM of resected ampullary adenocarcinomas (AC): an analysis of the French Fédération Française de Cancérologie Digestive AC prospective cohort study
Anna Pellat, Sylvain Manfredi, Stéphanie Truant, et al.
Eclinicalmedicine
|
June 8, 2026
Sequential alternation of nal-IRI/5-FU and gemcitabine/nab-paclitaxel versus nal-IRI/5-FU versus gemcitabine/nab-paclitaxel in first-line metastatic pancreatic cancer: results of the randomized phase II PRODIGE 61-FUNGEMAX trial (France)
Julien Taieb, Simon Pernot, Frédéric Thuillier, et al.
Blood
|
December 14, 2023
A p53 score derived from TP53 CRISPR/Cas9 HMCLs predicts survival and reveals a major role of BAX in the response to BH3 mimetics
Romane Durand, Géraldine Descamps, Céline Bellanger, et al.
Hematological Oncology
|
May 31, 2020
Whole genome copy number analysis in search of new prognostic biomarkers in first line treatment of mantle cell lymphoma. A study by the LYSA group
Yannick Le Bris, Florence Magrangeas, Anne Moreau, et al.
Page
of 26
Search research articles
Search
Showing results (241-250 of 260) with videos related to
Sort By:
Page
of 26
Hemasphere
|
October 9, 2024
Combined inhibition of CTPS1 and ATR is a metabolic vulnerability in p53-deficient myeloma cells
Romane Durand, Céline Bellanger, Géraldine Descamps, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 14, 2026
Efficacy of targeted therapies for metastatic small bowel adenocarcinoma treatment: A retrospective study by AGEO
Emeric Boisteau, Alice Boilève, David Tougeron, et al.
ESMO Real World Data and Digital Oncology
|
February 6, 2026
Characteristics and impact of real-world evidence studies in oncology: comprehensive mapping review of publications evaluating targeted therapies in solid tumours
A Pellat, T Grinda, P Cresta Morgado, et al.
Blood
|
August 10, 2023
CARD11 gain of function upregulates BCL2A1 expression and promotes resistance to targeted therapies combination in B-cell lymphoma
Salomé Decombis, Celine Bellanger, Yannick Le Bris, et al.
Addiction (Abingdon, England)
|
March 22, 2022
Effectiveness and cost-effectiveness of face-to-face and electronic brief interventions versus screening alone to reduce alcohol consumption among high-risk adolescents presenting to emergency departments: three-arm pragmatic randomized trial (SIPS Junior high risk trial)
Paolo Deluca, Simon Coulton, Mohammed Fasihul Alam, et al.
Blood Advances
|
December 12, 2018
p53 regulates CD46 expression and measles virus infection in myeloma cells
Anne Lok, Geraldine Descamps, Benoit Tessoulin, et al.
Gastrointestinal Endoscopy
|
February 19, 2026
Ability of computed tomography and endoscopic ultrasound to predict pTNM of resected ampullary adenocarcinomas (AC): an analysis of the French Fédération Française de Cancérologie Digestive AC prospective cohort study
Anna Pellat, Sylvain Manfredi, Stéphanie Truant, et al.
Eclinicalmedicine
|
June 8, 2026
Sequential alternation of nal-IRI/5-FU and gemcitabine/nab-paclitaxel versus nal-IRI/5-FU versus gemcitabine/nab-paclitaxel in first-line metastatic pancreatic cancer: results of the randomized phase II PRODIGE 61-FUNGEMAX trial (France)
Julien Taieb, Simon Pernot, Frédéric Thuillier, et al.
Blood
|
December 14, 2023
A p53 score derived from TP53 CRISPR/Cas9 HMCLs predicts survival and reveals a major role of BAX in the response to BH3 mimetics
Romane Durand, Géraldine Descamps, Céline Bellanger, et al.
Hematological Oncology
|
May 31, 2020
Whole genome copy number analysis in search of new prognostic biomarkers in first line treatment of mantle cell lymphoma. A study by the LYSA group
Yannick Le Bris, Florence Magrangeas, Anne Moreau, et al.
Page
of 26